GSK plc GSK announced that the U.S. Centers for Disease Control and Prevention’s (“CDC”) Advisory Committee on Immunization Practices (“ACIP”) voted favorably, recommending the use of Penmenvy ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

In this report, we summarize the findings of 10 phase 3 and 4 clinical studies evaluating coadministration of the quadrivalent meningococcal ... other vaccine antigens, namely, certain PCV and ...

A vaccine against meningococcal disease or any other disease works by generating an immune response in the body against some kind of pathogen—a virus, bacterium, or some other agent that causes ...

Pentavalent vaccines can reduce the number of injections required to help protect against invasive meningococcal disease – especially disease caused by serogroup B. Their use could improve ...

Background: Given the broad age range across which the quadrivalent meningococcal conjugate vaccine MenACWY-CRM ... Haemophilus influenzae type b, pneumococcal conjugate, measles–mumps–rubella ...

GSK's MenABCWY vaccine combines the antigenic components of the Company's two well-established meningococcal vaccines-Bexsero (Meningococcal Group B Vaccine) and Menveo (Meningococcal [Groups A ...